Diana Leykina, MD
General Practice · San Francisco, CANPI 1932355310
Payments from drug & device makers
Across 259 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$471
- AstraZeneca$442
- GSK$438
- Novo Nordisk$396
- Pfizer$372
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,788100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $1,462 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $471 |
| AstraZeneca | 16 | $442 |
| GSK | 19 | $438 |
| Novo Nordisk | 18 | $396 |
| Pfizer | 16 | $372 |
| Ironwood Pharmaceuticals, Inc | 17 | $311 |
| Nestle Healthcare Nutrition Inc. | 8 | $196 |
| Aimmune Therapeutics, Inc. | 8 | $194 |
| Novartis | 8 | $190 |
| Lilly USA, LLC | 7 | $172 |
| Amarin Pharma, Inc. | 7 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $132 |
| Johnson & Johnson | 6 | $119 |
| Amgen | 4 | $105 |
| Arbor Pharmaceuticals, Inc. | 4 | $74 |
| Eisai Inc. | 3 | $64 |
| Avanir Pharmaceuticals, Inc. | 2 | $56 |
| Boehringer Ingelheim | 2 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Astellas Pharma US Inc | 3 | $42 |
| Ardelyx, Inc. | 1 | $31 |
| Edwards Lifesciences | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
| Smith+Nephew | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,788 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 772 | $324,013 |
| CreonLipase/Protease/Amylase | 237 | $241,315 |
| LinzessLinaclotide | 261 | $136,371 |
| ZenpepLipase/Protease/Amylase | 124 | $134,516 |
| JardianceEmpagliflozin | 126 | $79,925 |
| VascepaIcosapent Ethyl | 232 | $69,478 |
| XareltoRivaroxaban | 171 | $67,380 |
| JanuviaSitagliptin Phosphate | 124 | $64,234 |
| Dexlansoprazole DrDexlansoprazole | 318 | $61,436 |
| TrulicityDulaglutide | 72 | $52,480 |
| OzempicSemaglutide | 51 | $51,976 |
| JanumetSitagliptin Phos/Metformin Hcl | 66 | $40,399 |
| RybelsusSemaglutide | 39 | $36,591 |
| MyrbetriqMirabegron | 114 | $32,500 |
| BelsomraSuvorexant | 67 | $28,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Namzaric, Alphagan P | $1,462 | $408,709611 claims |
| PfizerEliquis | $372 | $324,013772 claims |
| Aimmune Therapeutics, Inc.Zenpep | $194 | $134,516124 claims |
| MerckJanuvia, Janumet, Belsomra | $18 | $133,277257 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Jentadueto | $55 | $127,447219 claims |
| Novo NordiskOzempic, Rybelsus | $396 | $88,56790 claims |
| Johnson & JohnsonXarelto | $119 | $67,380171 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $74 | $52,523197 claims |
| Lilly USA, LLCTrulicity | $172 | $52,48072 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $438 | $34,39261 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $32,500114 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant | $132 | $31,73561 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in San Francisco
- Jared AdamsSan Francisco$862K
- Matthew YoungSan Francisco$127K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Marina GoldGlendale$784K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.